Deals this week: Biohaven Therapeutics, POXEL, Ossianix

7th September 2018 (Last Updated August 12th, 2019 10:38)

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease.

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease.

Developed by AstraZeneca, AZD3241 is an orally absorbed and centrally penetrant inhibitor of human myeloperoxidase and has been renamed as BHV3241.

Based in the US, Biohaven is a clinical-stage biopharmaceutical company that develops drug candidates for neurological diseases, while AstraZeneca is a UK-based biopharmaceutical company.

The in-licensing of BHV3241 will enable Biohaven to expand its portfolio of novel and late-stage drug candidates indicated for the treatment of neurologic and psychiatric disorders.

POXEL has completed the acquisition of DeuteRx’s DRX-065, which is indicated for the treatment of non-alcoholic steatohepatitis (NASH).

DeuteRx will receive an upfront cash payment of €6.8m ($8m) from Poxel, in addition to the 1.29 million ordinary shares of the latter’s common stock, as per the agreement.

DeuteRx will also receive milestone payments and royalties, upon the commercialisation of the drug.

Based in France, Poxel is a biopharmaceutical company specialising in the development of novel drugs for metabolic diseases, while DeuteRx is a clinical-stage biopharmaceutical company based in the US.

The acquisition of DRX-065 from DeuteRx enables Poxel to expand its metabolic pipeline.

"POXEL has completed the acquisition of DeuteRx’s DRX-065, which is indicated for the treatment of non-alcoholic steatohepatitis (NASH)."

Goodwin Procter has been appointed as the legal adviser to Poxel for the transaction.

Ossianix has signed a research and option agreement with Novo Nordisk on Blood Brain Barrier (BBB) technology to deliver proteins in diabetes and other metabolic disorders.

Ossianix will use its patented single domain and highly versatile variable new antigen receptor (VNAR) antibodies for the rapid delivery of therapeutic agents, while Novo Nordisk will be responsible for the commercialisation of the therapeutic products.

Novo Nordisk will pay upfront and milestone payments, research and development financing, and royalties to Ossianix, under the agreement.

Based in the US, Ossianix is a developer of single-domain antibodies based on VNAR structure, while Novo Nordisk is a Denmark-based healthcare company focused on developing medicines for diabetes care.

The transaction enables the two companies to develop drug candidates for disorders associated with the central nervous system (CNS).

Citoxlab has entered a partnership agreement with Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO).

Based in France, Citoxlab is a provider of pre-clinical services for the pharmaceutical sector, while EPO is a pathology and histopathology services provider based in Germany.

The strategic collaboration enables Citoxlab to strengthen its portfolio, which includes pharmacology and drug safety.